Antifungal activity of dexamethasone against fluconazole-resistant Candida albicans and its activity against biofilms

Future Microbiol. 2022 May:17:607-620. doi: 10.2217/fmb-2021-0146. Epub 2022 Apr 12.

Abstract

Objective: The present study investigated the antifungal action of dexamethasone disodium phosphate (Dex). Methodology: Susceptibility testing was performed using the Clinical & Laboratory Standards Institute protocol; M27-A3, checkerboard test and biofilm were evaluated with two isolates of Candida albicans, hyphal production test, molecular docking analysis and flow cytometry analysis. Result: Dex and fluconazole (FLC) together had a synergistic effect. Mature biofilm was reduced when treated with Dex alone or in combination. Dex and FLC promoted a decrease in the production of hyphae and changes in the level of mitochondrial depolarization, increased generation of reactive oxygen species, loss of membrane integrity, increased phosphatidylserine externalization and molecular docking; there was interaction with ALS3 and SAP5 targets. Conclusion: Dex showed antifungal activity against FLC-resistant C. albicans strains.

Keywords: Candida spp.; biofilm; dexamethasone; repositioning.

Plain language summary

This study aimed to evaluate the antifungal action of dexamethasone against FLC-resistant C. albicans strains.

MeSH terms

  • Antifungal Agents / pharmacology
  • Biofilms
  • Candida albicans*
  • Dexamethasone / pharmacology
  • Drug Resistance, Fungal
  • Drug Synergism
  • Fluconazole* / pharmacology
  • Microbial Sensitivity Tests
  • Molecular Docking Simulation

Substances

  • Antifungal Agents
  • Dexamethasone
  • Fluconazole